Piramal Pharma says it will base its response to renewed tariff concerns on actual policy decisions rather than informal public remarks. Speaking on the issue, Nandini Piramal indicated that the company is watching concrete government action instead of reacting to every headline around possible tariff changes.
A key part of that approach is Piramal Pharma’s manufacturing footprint across multiple regions, including India and the US. That network is seen as a strategic advantage because it can give the company more flexibility if trade conditions shift and tariffs affect how pharmaceutical products are made or supplied.
The company also remains positive on opportunities in the contract development and manufacturing business, an area that has become increasingly important for pharmaceutical outsourcing. Piramal Pharma appears to be positioning itself to benefit from demand in that segment while keeping an eye on how global policy developments could influence costs and operations.
Alongside that, the company is continuing to look at expansion as part of its broader growth plans. The overall message from management is that Piramal Pharma intends to stay focused on long-term execution, using its global manufacturing base and CDMO opportunity set to navigate uncertainty around tariffs.
